drugset / Trial / NCT00361309
SU011248 in Advanced Hepatocellular Carcinoma
Phase 2
Completed
34 enrolled
Massachusetts General Hospital
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabDana-Farber Cancer Institute · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further.
Timeline
- Start
- 2006-04
- Primary completion
- 2007-11
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |